After J&J-Synthes Deal, Will Orthopedic Consolidation Hit Zimmer, Stryker?
This article was originally published in The Gray Sheet
Executive Summary
In the wake of Johnson & Johnson’s $21.3 billion purchase of orthopedic implant maker Synthes, other large ortho firms like Zimmer and Stryker may face growing pressure to make their own acquisitions in order to stay competitive, market watchers speculate.
You may also be interested in...
Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz
Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.
Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz
Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.
J&J Doubles Down On Orthopedics With Synthes Deal; Takes Lead In Trauma
Johnson & Johnson will control a majority of the orthopedic trauma device market and double its stake in the spinal device field by acquiring Synthes for $21.3 billion under a definitive agreement announced April 27.